Science
The Science section contains AAN resources that are relevant to the academic neurologist and to those who follow scientific developments in neurology, whether basic, translational, or purely clinical.
The site contains information regarding AAN scientific awards and training grants, news and resources related to the NINDS, and information related to the AAN Science Committee and its role in planning the scientific aspects of the AAN Annual Meeting.
Science at the Annual Meeting
The AAN Annual Meeting brings together more than 12,000 neuroscience professionals for one of the world's largest neurology gatherings. It has long been a leading showcase for the latest developments in scientific research, and the place to honor peers at the forefront of the work.
Breakthrough research is always one of the Annual Meeting's biggest draws, and New Orleans will be no exception. Highlights include:
Emerging Science Abstracts
NOTE: The 2012 Emerging Science Abstract Submission deadline has passed.
Residents and Fellows: Sign up for Futures in Clinical Research Luncheon and Mentoring Sessions
Junior members are encouraged to attend two events at the Annual Meeting in New Orleans that will help them learn about careers in clinical research.
The Futures in Clinical Research Luncheon will be on Monday, April 23, from 12:00 p.m. to 1:30 p.m. The luncheon will provide a general overview of a career in clinical research and give residents and fellows an opportunity to interact with senior clinical researchers. Residents and fellows must sign up to attend this event.
On Tuesday, April 24, from 12:00 p.m. to 1:30 p.m., smaller mentoring sessions in six subspecialty areas will be offered. The groups presenting the sessions include:
- American Epilepsy Society
- Muscular Dystrophy Association
- Parkinson Study Group/Parkinson’s Disease Foundation
- Child Neurology Society
- National Multiple Sclerosis Society
- Alzheimer’s Association
Information about fellowships, educational opportunities, and how to identify and obtain research funding will be presented. Residents and fellows must also sign up to attend these sessions.
Roseanna Battista, administrative manager with the Parkinson Study Group, took part in the mentoring sessions in 2011. “Residents and fellows gain valuable information that is needed as they begin to develop a clinical research career,” she said. “They also hear from exceptional mentors who provide practical advice about applying for a fellowship, grant writing, identifying funding sources, negotiating a position and optimizing mentoring experiences. These sessions provide an opportunity for residents and fellows to network and interact with these mentors—an opportunity extolled by past attendees.”
In order to attend these events, you must register with the AAN.
For more information or to sign up for the Futures in Clinical Research Luncheon, contact Erin Jackson at ejackson@aan.com or (651) 695-2704.
Abstract Submissions
The 2012 Abstract Submission deadline has passed. Abstract notifications will be sent in late January 2012.
Read recent AAN Science Press Releases.
Watch for Emails Announcing Reviews of New MS Drugs
The AAN and its Multiple Sclerosis Section, led by Section Chair Robert P. Lisak, MD, FAAN, are working with a task force including the MS Coalition to make neurologists and the public aware of the known benefits and risks of newly emerging, FDA-approved medications for multiple sclerosis. AAN members will be alerted by email when reports on new medications are posted on the MS Coalition website.
This task force—dubbed the Multiple Sclerosis Emerging Therapies Collaborative—has established a dedicated rapid-response website that will provide information on new therapies as they emerge. The content is tailored to both clinicians and the general public, to facilitate effective communication and medical decision making. The AAN and MS Coalition members all have a stake in ensuring their constituencies receive the most accurate drug information, given there are a large number of competing information sources.
Review of New Drug Dextromethorphan Hydrobromide and Quinidine Sulfate to Treat PBA Available
The Multiple Sclerosis Emerging Therapies Collaborative has published information sheets on the multiple sclerosis medication dextromethorphan hydrobromide and quinidine sulfate (DM/QS, also known as Nuedexta). The medication is approved to treat pseudobulbar affect (PBA). AAN members can access the sheets, which include known benefits and risks, as well as answers to commonly asked questions, at www.ms-coalition.org/EmergingTherapies.
Read the information sheets now.
The content is tailored to suit both clinicians and the public to facilitate effective communication and medical decision making. The AAN and MS Coalition members all have a stake in ensuring their constituencies receive the most accurate drug information, given there are a large number of competing information sources.
For more information, contact emergingtherapies@ms-coalition.org.
